Anti-Vinculin antibody [SPM227]
| Name | Anti-Vinculin antibody [SPM227] |
|---|---|
| Supplier | Abcam |
| Catalog | ab18058 |
| Prices | $404.00 |
| Sizes | 500 µl |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | SPM227 |
| Applications | FC ICC/IF ICC/IF WB IP IHC-P |
| Species Reactivities | Mouse, Rat, Hamster, Human |
| Antigen | Full length native protein (semi-purified) (Human) |
| Description | Mouse Monoclonal |
| Gene | VCL |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
ab18058 at 1/200 staining Chinese Hamster Ovary cells by ICC/IF. The cells were permeabilized with 100% methanol and then blocked with 1% BSA/ 4% goat serum prior to incubation with the antibody for 30 minutes. A rhodamine conjugated goat antibody was used as the secondary.See Abreview
ab18058 staining mouse 3T3 cells by ICC/IF. Cells were PFA fixed and permeabilized in Triton X-100 prior to blocking in 1% BSA for 30 minutes at 25°C. The primary antibody was diluted 1/100 and incubated with the sample for 1 hour at 25°C, ab6785, diluted 1/100, was used as the secondary antibody.See Abreview
![Anti-Vinculin antibody [SPM227] (ab18058) at 1/1000 dilution + Whole cell lysate prepared from human lung cells at 40 µgSecondaryHRP conjugated goat polyclonal to mouse IgG at 1/1000 dilution](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/20038_Vinculin-Primary-antibodies-ab18058-3.jpg)
Anti-Vinculin antibody [SPM227] (ab18058) at 1/1000 dilution + Whole cell lysate prepared from human lung cells at 40 µgSecondaryHRP conjugated goat polyclonal to mouse IgG at 1/1000 dilution
Ab18058 staining human normal prostate. Staining is localised to the nucleus and cytoplasm.Left panel: with primary antibody at 1 ug/ml. Right panel: isotype control.Sections were stained using an automated system DAKO Autostainer Plus , at room temperature. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 AR buffer citrate pH 6.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS), then incubated with primary antibody for 20 minutes, and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.
ICC/IF image of ab18058 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab18058, 10µg/ml) overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti-mouse IgG - H&L, pre-adsorbed (ab96879) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
![Overlay histogram showing HeLa cells stained with ab18058 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab18058, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/20042_Vinculin-Primary-antibodies-ab18058-19.jpg)
Overlay histogram showing HeLa cells stained with ab18058 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab18058, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.
Product References
A conserved C-terminal sequence of high-risk cutaneous beta-human papillomavirus - A conserved C-terminal sequence of high-risk cutaneous beta-human papillomavirus
Holloway A, Storey A. J Gen Virol. 2014 Jan;95(Pt 1):123-34.
Protective role of miR-155 in breast cancer through RAD51 targeting impairs - Protective role of miR-155 in breast cancer through RAD51 targeting impairs
Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro CL, Huebner K, Croce CM. Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4536-41. doi:
Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via - Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via
He WA, Calore F, Londhe P, Canella A, Guttridge DC, Croce CM. Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4525-9. doi:
On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, - On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor,
Gehrke I, Bouchard ED, Beiggi S, Poeppl AG, Johnston JB, Gibson SB, Banerji V. Clin Cancer Res. 2014 Sep 15;20(18):4861-72.
Fhl1 W122S causes loss of protein function and late-onset mild myopathy. - Fhl1 W122S causes loss of protein function and late-onset mild myopathy.
Emmanuele V, Kubota A, Garcia-Diaz B, Garone C, Akman HO, Sanchez-Gutierrez D, Escudero LM, Kariya S, Homma S, Tanji K, Quinzii CM, Hirano M. Hum Mol Genet. 2015 Feb 1;24(3):714-26.
Disc1 variation leads to specific alterations in adult neurogenesis. - Disc1 variation leads to specific alterations in adult neurogenesis.
Chandran JS, Kazanis I, Clapcote SJ, Ogawa F, Millar JK, Porteous DJ, Ffrench-Constant C. PLoS One. 2014 Oct 1;9(10):e108088.
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating - MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. Nat Commun. 2013;4:1393.
FANC pathway promotes UV-induced stalled replication forks recovery by acting - FANC pathway promotes UV-induced stalled replication forks recovery by acting
Renaud E, Rosselli F. PLoS One. 2013;8(1):e53693.
Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of - Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of
Galli R, Paone A, Fabbri M, Zanesi N, Calore F, Cascione L, Acunzo M, Stoppacciaro A, Tubaro A, Lovat F, Gasparini P, Fadda P, Alder H, Volinia S, Filippini A, Ziparo E, Riccioli A, Croce CM. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9812-7. doi:
The intersection of genetic and chemical genomic screens identifies GSK-3alpha as - The intersection of genetic and chemical genomic screens identifies GSK-3alpha as
Banerji V, Frumm SM, Ross KN, Li LS, Schinzel AC, Hahn CK, Kakoza RM, Chow KT, Ross L, Alexe G, Tolliday N, Inguilizian H, Galinsky I, Stone RM, DeAngelo DJ, Roti G, Aster JC, Hahn WC, Kung AL, Stegmaier K. J Clin Invest. 2012 Mar;122(3):935-47.